Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Teva Pharmaceutical Industries Ltd. announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.


Previous Article Next Article

Today in M&A/Partnerships...keeping you current

New graduate degree offered focusing on health care quality
National Committee for Quality Assurance (NCQA), 06/11/09

GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
PharmExec, 06/04/09

Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody
Sanofi-aventis, 05/15/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address